湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 湖南方盛制药股份有限公司 分红管理制度 （已经 2024 年第二次临时股东大会审议通过） 第一章 总则 第一条 为进一步规范湖南方盛制药股份有限公司（以下简 称"公司"）的分红行为，建立科学、持续、稳定的分红机制， 充分保护中小投资者合法权益，公司根据中国证券监督管理委员 会（以下简称"中国证监会"）《关于进一步落实上市公司现金 分红有关事项的通知》《上市公司监管指引第 3 号——上市公司 现金分红（2023 年修订）》等法律法规及规范性文件，以及《湖 南方盛制药股份有限公司章程》（以下简称"公司章程"），结 合公司实际情况，制定本制度。 第二章 利润分配和现金分红政策 第二条 公司重视对投资者特别是中小投资者的合理投资回 报，制定科学、持续、稳定的分红政策。 第三条 利润分配原则： （一）公司利润分配应重视对投资者的合理投资回报，充分 维护公司股东依法享有的资产收益权。 （二）公司当年实现盈利，在符合规定的利润分配条件的情 况下，除《公司章程》规定的特殊情况外，公司将优先采取现金 方式分配股利。 （三） ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company is steadily increasing its innovative traditional Chinese medicine products, with the recent submission of a listing application for the "Yingxue Qufeng Zhitong Granules" [1] - The new product has significant market potential, addressing a large patient population suffering from tension-type headaches, with approximately 1.04 billion people globally affected by migraines [1] - The company reported a revenue of 910 million yuan for the first half of 2024, a year-on-year increase of 6.44%, and a net profit attributable to shareholders of 137 million yuan, up 28.23% year-on-year [1] Financial Performance - In Q2 2024, the company achieved a revenue of 472 million yuan, a year-on-year increase of 12.77%, and a net profit of 67 million yuan, up 55.26% year-on-year [1] - The overall gross margin for the first half of 2024 was 72.66%, an increase of 3.47 percentage points year-on-year, driven by a decrease in raw material costs [1] - The company has cultivated four products with annual sales exceeding 100 million yuan, including "Tenghuang Jianguo Pian" and "Qiangli Pipa Gao" [2] Revenue and Profit Forecast - The revenue forecast for 2024-2026 is adjusted to 1.737 billion, 2.026 billion, and 2.364 billion yuan, with year-on-year growth rates of 7%, 17%, and 17% respectively [4] - The net profit attributable to shareholders is projected to be 225 million, 300 million, and 352 million yuan for 2024-2026, with year-on-year growth rates of 21%, 33%, and 17% respectively [4] - The company maintains a focus on optimizing its product structure, leading to a steady increase in gross margins [4] R&D and Innovation - The company continues to increase its R&D investment, with recent approvals for clinical trials of innovative traditional Chinese medicine products [3] - The focus on core business areas and clear future direction is enhancing the company's competitive advantages and profitability [3]

Group 1: Event Announcement - Hunan Fangsheng Pharmaceutical Co., Ltd. will participate in the "2024 Annual Investor Online Collective Reception Day" organized by Hunan Securities Regulatory Bureau, Hunan Listed Companies Association, and Shenzhen Panorama Network Co., Ltd. [2] - The event will be held online on October 10, 2024, from 14:00 to 17:00 [2]. Group 2: Participation Details - Investors can participate via the "Panorama Roadshow" website, WeChat official account, or by downloading the Panorama Roadshow APP [2]. - Company executives will communicate with investors regarding the company's performance from 2023 to the first half of 2024, governance, development strategy, operational status, financing plans, equity incentives, and sustainable development [2]. Group 3: Company Assurance - The board of directors guarantees that the announcement contains no false records, misleading statements, or significant omissions, and they bear legal responsibility for the content's truthfulness, accuracy, and completeness [2].

特此公告 湖南方盛制药股份有限公司监事会 2024 年 9 月 19 日 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603998 证券简称：方盛制药 公告编号：2024-077 湖南方盛制药股份有限公司（以下简称"公司"）第五届监 事会 2024 年第七次临时会议于 2024 年 9 月 18 日下午 16:00 在 新厂办公大楼一楼会议室（一）召开。会议通知已于 2024 年 9 月 14 日以书面形式告知全体监事。本次会议由公司监事会主席 肖满女士召集并主持，会议应出席监事 3 人，实际出席监事 3 人。 公司董事会秘书列席了本次会议。本次会议召开符合法律、法规、 规章及《公司章程》的有关规定，会议合法、有效。会议审议并 通过了《关于就放弃参股子公司增资权及其他相关事项签署经修 订及重述的协议的议案》（表决情况：同意 3 票，反对 0 票，弃 权 0 票，表决通过。） 湖南方盛制药股份有限公司 第五届监 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2024-078 湖南方盛制药股份有限公司 关于转让控股子公司部分股权暨引进战略投资者的 进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 截至2024年6月30日，佰骏医疗贷款未偿还公司本金为人民币155,188,251元， 应计利息为人民币2,404,354.97元。本次交易中，德维塔公司向长沙佰骏提供相当于人 民币8,000万元的美元借款（本次提款资金），该笔借款全部用于帮助佰骏医疗归还公 司股东贷款，最终由佰骏医疗通过下属医院现金流置换等合法合规的方式来偿还公司提 供给其的股东贷款。公司将持有的佰骏医疗1.36%股权（相当于人民币7,065,200元）无 偿转让给德维塔公司，作为德维塔公司向长沙佰骏提供本次提款资金并用该笔资金帮助 佰骏医疗偿还公司贷款的补偿； 佰骏医疗应从2025年开始在每个季度向公司偿还人民币不少于600万元，首次 偿 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2024-076 湖南方盛制药股份有限公司 关于全资子公司收到药品注册受理通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 风险提示 由于医药产品具有高科技、高风险、高附加值的特点，药品研发容易受到技术、审 批、政策等多方面因素的影响，药品审评审批时间、审批结果及未来产品市场竞争形势均存 在诸多不确定性。敬请广大投资者谨慎决策，注意防范投资风险。 2024 年 8 月，湖南方盛制药股份有限公司（以下简称"公 司"）全资子公司广东方盛健盟药业有限公司（以下简称"健盟 药业"）完成养血祛风止痛颗粒（曾用名：诺丽通颗粒）的长毒 试验，并向国家药品监督管理局（以下简称"国家药监局"）提 交上市许可申请。2024 年 9 月 13 日，健盟药业收到养血祛风止 痛颗粒《受理通知书》。现将相关情况公告如下： 一、药品基本情况 1、药品名称：养血祛风止痛颗粒 2、剂型：颗粒 ...

目 录 2024 年第二次临时股东大会 会议资料 中国湖南 长沙 2024 年 9 月 27 日 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. | 2024 | 年第二次临时股东大会会议议程 | | 3 | | --- | --- | --- | --- | | 2024 | 年第二次临时股东大会会议须知 | | 5 | | 议案 | 1：关于制定《公司分红管理制度》的议案 | | 6 | | 议案 | 2：关于 2024 年半年度利润分配方案的预案 | | 7 | 第 2 页，共 7 页 湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 2024 年第二次临时股东大会会议议程 会议时间：2024 年 9 月 27 日下午 14:30 会议地点：公司新厂办公大楼一楼会议室（一）（长沙市国家高新技术产业 开发区嘉运路 299 号） 会议召集人：公司董事会 大会主持人：董事长周晓莉女士 大会议程： ★ 签到、宣布会议开始 一、与会人员签到，领取会议资料；股东及股东代理人同时提交身份证明材 料（授权委 ...

湖南方盛制药股份有限公司 HUNANFANGSHENG PHARMACEUTICAL CO., LTD. 证券代码：603998 证券简称：方盛制药 公告编号：2024-075 湖南方盛制药股份有限公司 关于为子公司提供非融资性担保的进展公告 乙方：锐新药业 经湖南方盛制药股份有限公司（以下简称"公司"）第五届 董事会 2021 年第四次临时会议、2021 年第二次临时股东大会分 别审议通过《关于为子公司提供担保的议案》，同意公司为湖南 方盛锐新药业有限公司（以下简称"锐新药业"）（公司直接持 有 100%股权）提供总额度不超过 10,000 万元的担保，公司已于 2024 年 8 月 20 日签订《药品上市许可持有人担保协议》（以下 简称"担保协议"）（详见公司 2021-030 号、2021-046、2024-065 号公告），现将本次担保事项进展公告如下： 一、本次担保的进展 为优化资产结构与资源配置，切实执行"归核化"的发展战 略。经董事长审批通过，公司于 2024 年 9 月 11 日与广州峰霖药 业有限公司（以下简称"峰霖药业"）签署《股权转让协议》， 将公司持有的全资子公司锐新药业 100%股权 ...

Financial Performance - In the first half of 2024, the company achieved operating revenue of 910.25 million yuan, a year-on-year increase of 6.44% compared to the first half of 2023 [1] - The net profit attributable to shareholders was 136.84 million yuan, reflecting a year-on-year growth of 28.23% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 110.71 million yuan, up 26.54% year-on-year [1] Research and Development - The company has initiated 13 innovative traditional Chinese medicine (TCM) projects in preclinical research, covering various medical fields including gynecology, orthopedics, respiratory, pediatrics, and oncology [2] - The innovative TCM product "Yiqi Xiaoliu Granules" has received approval for clinical trials from the National Medical Products Administration [2] Product Sales - Revenue from respiratory system medications reached 146.32 million yuan in the first half of 2024, a year-on-year increase of 12.09%, primarily driven by strong sales of "Qiangli Pipa Gao" [2] - "Qiangli Pipa Gao" generated sales of 135 million yuan, with a growth of over 26% year-on-year, while "Qiangli Pipa Lu" saw a decline of approximately 52% with sales of 11.27 million yuan [2] - The innovative TCM products "Xiaoer Jingxing Zhi Ke Granules" and "Xuanqi Jianguo Pian" have shown promising market expansion, with the former covering over 1,500 public medical institutions by June 30, 2024, and achieving sales of approximately 45 million yuan, a growth of over 150% [2][3] Future Outlook - The company anticipates a revenue growth of no less than 5% year-on-year for 2024, considering the impact of national centralized procurement on product pricing [4] - The net profit attributable to shareholders is expected to grow between 20% and 35% year-on-year [4] - The management emphasizes the importance of market conditions, operational environment, and industry policies in achieving these targets, highlighting the inherent uncertainties [4]

Investment Rating - The report maintains a "Buy" rating for the company, expecting a relative performance increase of over 15% compared to the benchmark index in the next 6 to 12 months [8]. Core Insights - The company reported a revenue of 910 million yuan for the first half of 2024, representing a year-on-year growth of 6.44%. The net profit attributable to shareholders was 137 million yuan, up 28.23% year-on-year [2]. - The second quarter performance exceeded expectations, with revenue reaching 472 million yuan, a year-on-year increase of 12.77%, and a net profit of 66.65 million yuan, up 55.26% year-on-year [4]. - The company is experiencing significant growth in its cardiovascular segment, with revenue of 238 million yuan, a year-on-year increase of 37.57% [4]. - The report anticipates revenue growth for 2024-2026 to be 1.899 billion, 2.216 billion, and 2.564 billion yuan, respectively, with net profit projections of 258 million, 314 million, and 390 million yuan [5]. Financial Performance Summary - **Revenue Forecast**: - 2022A: 1,792 million yuan - 2023A: 1,629 million yuan - 2024E: 1,899 million yuan - 2025E: 2,216 million yuan - 2026E: 2,564 million yuan - Year-on-year growth rates: 14.4%, -9.1%, 16.6%, 16.7%, 15.7% [1] - **Net Profit Forecast**: - 2022A: 286 million yuan - 2023A: 187 million yuan - 2024E: 258 million yuan - 2025E: 314 million yuan - 2026E: 390 million yuan - Year-on-year growth rates: 308.1%, -34.6%, 38.1%, 21.9%, 24.2% [1] - **Earnings Per Share**: - 2022A: 0.65 yuan - 2023A: 0.42 yuan - 2024E: 0.59 yuan - 2025E: 0.71 yuan - 2026E: 0.89 yuan [1] - **Valuation Ratios**: - P/E: 16.9, 25.9, 18.8, 15.4, 12.4 - P/B: 3.5, 3.3, 3.0, 2.6, 2.3 [1] Business Segment Performance - **Cardiovascular**: Revenue of 238 million yuan, up 37.57% year-on-year, with a standout product showing over 110% sales growth [4]. - **Orthopedics**: Revenue of 193 million yuan, up 3.62% year-on-year, with core products showing steady growth [4]. - **Respiratory**: Revenue of 146 million yuan, up 12.09% year-on-year, with significant growth in key products [4]. - **Pediatrics**: Revenue of 94.07 million yuan, down 3.50% year-on-year, but with notable growth in specific products [4].